A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus.
A 23 kDa peptide of the major structural protein of the hepatitis E virus (HEV) expressed in E. coli was found to naturally interact with one another to form homodimers and the peptide was recognized strongly in its dimeric form by HEV reactive human sera. To determine if the peptide may confer protection against HEV infection, three monkeys were immunized with the purified peptide and three were given placebo. Both groups of animals were challenged with 10(5) genome equivalent dose of the homologous strain of HEV. All control animals excreted the virus for 10-12 days beginning 5 days after the infection. The viral genome was also present in the peripheral blood monocyte (PBMC) samples from two animals, but it was not detected in the plasma samples from any of the animals. The infection in two control animals was accompanied by HEV seroconversion. Immunization was found to abrogate HEV stool excretion in two animals and reduced the viral excretion to one day in the third. None of the immunized animals showed detectable HEV in plasma or PBMC samples nor did the animals showed evidence of HEV seroconversion. These results suggested that immunization with the bacterially expressed peptide may prevent experimental infection of primates with the homologous strain of HEV.
Im
S W
SW
Department of Microbiology, Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital Compound SAR, Hong Kong, People's Republic of China.
Zhang
J Z
JZ
Zhuang
H
H
Che
X Y
XY
Zhu
W F
WF
Xu
G M
GM
Li
K
K
Xia
N S
NS
Ng
M H
MH
D000818:Animals; D004926:Escherichia coli / Q000235:genetics*; D005982:Glutathione Transferase / Q000096:biosynthesis; D016751:Hepatitis E / Q000517:prevention & control* / Q000821:virology; D016752:Hepatitis E virus / Q000276:immunology*; D007115:Immunization Schedule; D008253:Macaca mulatta; D010455:Peptides / Q000235:genetics* / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification
D010455:Peptides; D011993:Recombinant Fusion Proteins; D014759:Viral Envelope Proteins; D005982:Glutathione Transferase